Connect your AI

Inspire Medical Systems INSP Price / book

Price / book at other companies

ResMedRMD

5×-0.9×

LivaNovaLIVN

2.9×+0.8×

Globus MedicalGMED

2.5×0.0×

ITG

Integer HoldingsITGR

1.8×-0.8×

MedtronicMDT

2.1×-0.1×

Intuitive SurgicalISRG

9.4×-1.0×

Other financials

Income statement

Revenue$204.6M+1.6%

Gross profit$176.9M+3.7%

Operating income-$1.1M+24.7%

Net income-$11.3M-477%

EPS (diluted)-$0.39-490%

Balance sheet

Cash & equivalents$98.9M+83.6%

Total debt$29.6M-11.8%

Total equity$792.3M+24.6%

Total assets$911.4M+24.7%

Cash flow

Operating cash flow$12.8M+292%

CapEx$9.7M+15.7%

Free cash flow$3.1M+121%

Valuation

Market cap$1.24B-67.6%

Enterprise value$1.18B-69.2%

P/E9.5×-48.2×

P/S1.4×-3.2×

Profitability

Gross margin85.8%+1.1pp

Operating margin5.6%-0.3pp

Net margin14.3%+6.4pp

FCF margin10.6%+1.2pp

Returns & leverage

Return on equity18.4%+7.5pp

Debt / equity0×0.0×

Current ratio6.3×-2.7×

Where this comes from

Calculated from Inspire Medical Systems’s reported figures.

market cap/total stockholders equity=1.9×

Based on the most recent quarter.

The official record: Inspire Medical Systems’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inspire Medical Systems's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Inspire Medical Systems's price / book?: Inspire Medical Systems (INSP) reported price / book of 1.9× in Q1 2026.
How has Inspire Medical Systems's price / book changed year-over-year?: Inspire Medical Systems's price / book decreased by 74.9% year-over-year, from 7.5× to 1.9×.
What is the long-term trend for Inspire Medical Systems's price / book?: Over 5 years (2020 to 2025), Inspire Medical Systems's price / book has grown at a -31.3% compound annual growth rate (CAGR), from 22.4× to 3.4×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.